Alteogen Inc.
Alteogen Inc. has 3 licensing announcements in this dataset, dated 2026-01-20 to 2026-09-02.
- Country / operating region
- South Korea
- Ticker
- 196170.KQ
- Headquarters
- 查無
- Founded
- 2008
- Business
- Biologics platform research and development
- Website
- alteogen.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| ALT-B4 | Hyaluronan; PD-1 | other | 查無 | 2026-01-20 |
| ALT-B4 | Hyaluronan | other | 查無 | 2026-03-25 |
| ALT-B4 | Hyaluronan | other | 查無 | 2026-09-02 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-01-20 | Tesaro, Inc. (GSK subsidiary) | ALT-B4 | USD 20m | 查無 | ≤ USD 265m | 查無 | — |
| 2026-03-25 | Biogen Inc. | ALT-B4 | USD 20m | 查無 | ≤ USD 549m | 查無 | Second-product initiation USD 10m |
| 2026-09-02 | Novartis Pharma AG | ALT-B4 | 查無 | 查無 | 查無 | ≤ USD 3223m | — |
| Counterparty | Territory | Royalties |
|---|---|---|
| Tesaro, Inc. (GSK subsidiary) | Worldwide | Royalties on sales of the commercialized product; rate not disclosed. |
| Biogen Inc. | 查無 | Royalties based on net sales; rate not disclosed in announcement. |
| Novartis Pharma AG | 查無 | A certain percentage of net sales of products incorporating ALT-B4 after first commercial sale; rate not disclosed. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無